Joshua Burgett, NP
Psychiatric/Mental Health · Sacramento, CANPI 1841378247
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $154,332 of the $239,247 with a category attached, or 64.5%. E.r. Squibb & Sons, L.L.C. accounts for 61.4% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $208,941, more than ten times the $230 reported in 2021. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 476 payments — averaging $502.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$147K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$80K
- Alkermes, Inc.$11K
- Johnson & Johnson$603
- AbbVie$274
- Janssen Scientific Affairs, LLC$263
- plus $405 from 3 others
What the payments were for
- Consulting fees$24,94310%
- Speaking & faculty fees$154,33265%
- Travel & lodging$46,52819%
- Food & beverage$13,4306%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 250 | $147,007 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 183 | $79,543 |
| Alkermes, Inc. | 26 | $11,152 |
| Johnson & Johnson | 7 | $603 |
| AbbVie | 3 | $274 |
| Janssen Scientific Affairs, LLC | 3 | $263 |
| Teva Pharmaceuticals USA, Inc. | 2 | $164 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Supernus Pharmaceuticals, Inc. | 1 | $116 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COBENFY$126,057
- CAPLYTA$76,126
- LYBALVI$24,233
- ARISTADA$18,613
- ARISTADA INITIO$3,615
- INVEGA SUSTENNA$697
- INVEGA TRINZA$349
- VRAYLAR$249
- Auvelity$125
- UZEDY$119
- QELBREE$116
How this compares
$239,247 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 34 | $106,224 |
| Clozapine | 174 | $22,414 |
| Lurasidone Hcl | 30 | $12,728 |
| Aripiprazole | 146 | $9,858 |
| Bupropion XlBupropion Hcl | 27 | $3,984 |
| Quetiapine Fumarate | 91 | $2,717 |
| Fluphenazine Hcl | 25 | $2,710 |
| Divalproex Sodium ErDivalproex Sodium | 73 | $2,647 |
| Olanzapine | 113 | $1,960 |
| Haloperidol | 77 | $1,658 |
| Duloxetine Hcl | 12 | $1,462 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 22 | $1,031 |
| Fluphenazine Decanoate | 17 | $928 |
| Ziprasidone Hcl | 37 | $912 |
| Prazosin Hcl | 51 | $716 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $603 | $106,22434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Sacramento
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
- Jonathan LlamasPasadena$31K
- John AdenijiRedlands$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.